1. Home
  2. INAB vs BNKK Comparison

INAB vs BNKK Comparison

Compare INAB & BNKK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo IN8bio Inc.

INAB

IN8bio Inc.

HOLD

Current Price

$1.44

Market Cap

13.7M

Sector

Health Care

ML Signal

HOLD

BNKK

Bonk Inc.

HOLD

Current Price

$1.28

Market Cap

13.0M

ML Signal

HOLD

Company Overview

Basic Information
Metric
INAB
BNKK
Founded
2016
2018
Country
United States
United States
Employees
N/A
10
Industry
Biotechnology: Pharmaceutical Preparations
Package Goods/Cosmetics
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
13.7M
13.0M
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
INAB
BNKK
Price
$1.44
$1.28
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$6.00
N/A
AVG Volume (30 Days)
40.1K
143.4K
Earning Date
05-11-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.17
$0.11
52 Week High
$2.73
$7.19

Technical Indicators

Market Signals
Indicator
INAB
BNKK
Relative Strength Index (RSI) 46.12 36.07
Support Level $1.32 $0.12
Resistance Level $1.53 $1.66
Average True Range (ATR) 0.08 0.09
MACD 0.01 0.01
Stochastic Oscillator 60.31 24.26

Price Performance

Historical Comparison
INAB
BNKK

About INAB IN8bio Inc.

IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.

About BNKK Bonk Inc.

Bonk Inc provides over-the-counter products and consumer products in the United States. The company offers Safety Shot Beverage, an over-the-counter drink that lowers blood alcohol content. It sells its products through direct customers, distributors, retailers, and e-commerce websites. The company generates revenue through various channels, its primary sales include nostingz suncare products which are sold through e-commerce platforms, licensing revenues from Photocil and sales of the Safety Shot Beverage. The company has two reportable segments: the dietary and energy beverage business and digital assets, consisting of investing for growth in the appreciation of the asset. It derives the majority of the revenue from the dietary and energy beverage segment.

Share on Social Networks: